Genedrive PLC logo

Genedrive PLC (GDR)

Market Closed
12 Aug, 15:30
LSE LSE
£
1. 16
-0.04
-3.0417%
£
10.32M Market Cap
- P/E Ratio
- Div Yield
627,734 Volume
- Eps
£ 1.2
Previous Close
Add Transaction
Day Range
1.15 1.25
Year Range
0.19 2.2
Want to track GDR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

GDR closed today lower at £1.16, a decrease of -3.0417% from yesterday's close, completing a monthly increase of 0% or £1.16. Over the past 12 months, GDR stock gained 0%.
GDR is not paying dividends to its shareholders.
The last earnings report, released on Nov 28, 2024, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBP).

GDR Chart

People also search for

RE
Colas S.A.
111 GBX
+0.9091%
HSS
HSS Hire Group PLC
£ 7.29
-1.3532%
SMJ
Smart (J) & Co (Contractors) Plc
112.5 GBX
0%
IKA
Ilika PLC
£ 25
0%
PCI-PAL PLC
£ 56.5
0%

Genedrive PLC (GDR) FAQ

What is the stock price today?

The current price is £1.16.

On which exchange is it traded?

Genedrive PLC is listed on LSE.

What is its stock symbol?

The ticker symbol is GDR.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 10.32M.

Has Genedrive PLC ever had a stock split?

No, there has never been a stock split.

Genedrive PLC Profile

Professional Services Industry
Industrials Sector
Dr. Gino Miele Ph.D. CEO
LSE Exchange
G3791Q102 CUSIP
United Kingdom Country
43 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Genedrive plc operates as a molecular diagnostics company focused on the research, development, and commercialization of point of need diagnostics platforms aimed at infectious diseases, genotyping, pathogen detection, and various other indications. The company, which was initially known as Epistem Holdings Plc, rebranded to Genedrive plc in July 2016. Since its inception in 2000, Genedrive plc has been contributing to the medical, biotechnology, and pharmaceutical sectors, offering innovative diagnostic solutions. Headquartered in Manchester, United Kingdom, the company has established a broad presence, serving clients across the United Kingdom, Europe, the United States, and other international markets.

Products and Services

Genedrive plc has developed and commercialized a range of diagnostic products and services, including:

  • Genedrive system: This product is a rapid thermocycler and signal detection system, which functions as a semi-automated system for qualitative in vitro molecular diagnostic tests. It is designed to provide swift and reliable diagnostic results at the point of need.
  • Genedrive CYP2C19 ID Kit: A point-of-care test specifically designed for rapid CYP2C19 genotyping. This is especially crucial in time-critical emergency care settings, where quick and informed decision-making can significantly impact patient outcomes.
  • Genedrive MT-RNR1-ID Kit: This rapid genetic test is aimed at use in emergency neonatal care settings. It's crafted for specific medical conditions that require immediate diagnosis to guide treatment decisions effectively right from the start.
  • Tests for Antibiotic Induced Hearing Loss in neonates: These diagnostic tests are crucial for detecting the risk of hearing loss induced by antibiotics in newborns, allowing for immediate adjustments in treatment plans to prevent potential hearing damage.
  • Confirmation of HCV infection: Genedrive's offering includes tests designed for the rapid confirmation of Hepatitis C virus infections prior to the commencement of drug treatment, streamlining the pathway to care.
  • Pathogen detection of biological military threats: The company also provides solutions for detecting a range of biological military threats, bolstering defense and preparedness strategies for military and national security organizations.
  • Point-of-care COVID-19 detection system: In response to the global pandemic, Genedrive developed a COVID-19 detection system suitable for use in a variety of settings, including healthcare, workplace screening, travel requirements, and for confirming antigen test results.

Contact Information

Address: The CTF Building
Phone: 44 16 1989 0245